Recurrence or metastasis of cancer has been considered to occur in the last stage of the patient’s life. However, the new notions of oligometastases and oligo-recurrence have been proposed and the paradigm shift in the conceptualization of cancer metastasis or cancer recurrence. Oligometastases is the state in which the patient shows distant relapse in only a limited number of regions. Local therapy such as surgery, radiotherapy and radiofrequency ablation for the relapsed sites could thus improve patient’s survival. On the other hand, oligo-recurrence is a notion similar to oligometastases. However, the conditions of oligo-recurrence has a primary site of the cancer controlled, meaning that all gross recurrent or metastatic sites could be treated using local therapy.

Key words: oligometastases – oligo-recurrence – local therapy – systemic therapy – paradigm shift

Oligometastases

Oligometastases is the state in which the patient shows distant relapse in only a limited number of regions. Local therapy such as surgery, radiotherapy and radiofrequency ablation for the relapsed sites could thus improve patient’s survival. The state of oligometastases (Fig. 1) represents an important concept, but one important problem remains to be solved. Oligometastases did not eliminate the uncontrolled primary site with several distant metastases. Then, all metastatic sites were thoroughly treated with local therapy, which did not lead to disappearance of all gross tumors and not might have achieved cure. As the primary site was not or could not be treated with local therapy, the primary site would exacerbate sooner.

Oligo-recurrence

Niibe et al. (2–4) proposed the new notion of oligo-recurrence to overcome these problems. Oligo-recurrence is a notion similar to oligometastases. However, the conditions of oligo-recurrence are: (i) one to several distant metastases/recurrences (usually one) in one to several organs (usually one); (ii) primary site of the cancer controlled; (iii) one to several distant metastases/recurrences can be treated with local therapy; and (iv) no other distant metastases/recurrences other than those in (iii). This state of oligo-recurrence is shown in Fig. 2 and the differences
between oligometastasis and oligo-recurrence are listed in Table 1. In the state of oligo-recurrence, recurrent or metastatic sites with a controlled primary lesion were treated with local therapy, meaning that all gross recurrent or metastatic sites could be treated using local therapy.

**SYSTEMIC THERAPY AND LOCAL THERAPY**

Improvement of systemic chemotherapy including molecular-targeted therapy has allowed micrometastases to be almost completely absent clinically. Theoretically, if several gross metastatic or recurrent sites could be eradicated by local therapy, these patients could be cured with concomitant systemic chemotherapy. Punglia et al. (5) reported that if systemic therapy improved, the role of local therapy would improve and proposed a figure for this correlation. Here, a new figure of the correlation between local therapy and systemic therapy is proposed (Fig. 3), showing that the role of local therapy is initially increasingly important as systemic therapy improves, depending on the sigmoid curve. The current status of cancer therapy lies in the range between 0 and A. However, in the future, extreme improvements in systemic therapy will decrease the importance of local therapy, because cancers will be diminished by systemic therapy alone such as intravenous anti-cancer drug infusion or oral anti-cancer drugs. All cancerous lesions including gross tumors and microinvasive tumors could be eradicated with systemic therapy alone. This desirable state is shown as B in Fig. 3. In the present status (range: 0–A in Fig. 3), systemic therapy is not yet powerful enough that local therapy is not required for eradication, particularly for gross tumor.

| Reference            | Oligometastases | Oligo-recurrence |
|----------------------|-----------------|------------------|
| Hellman and Weichselbaum (1) |                 | Niibe et al. (2,3,4) |
| Primary lesion       | Uncontrolled/controlled | Controlled       |
| No. of distant/metastases/recurrences | One to several | One to several (one is better) |

**Figure 1.** This is a schema of oligometastases. Schema 1 shows one distant metastasis/recurrence with a primary lesion. Schema 2 shows two distant metastases/recurrences with a primary lesion.

**Figure 2.** This is a schema of oligo-recurrence. Schema 1 shows one distant metastasis/recurrence with a controlled primary lesion. Schema 2 shows two distant metastases/recurrences with a controlled primary lesion. The biggest difference between oligometastases and oligo-recurrences lies in the uncontrolled or controlled primary lesion. Oligo-recurrence requires a controlled primary lesion.

**Figure 3.** This shows correlations between systemic and local therapies. Until point A, the role of local therapy increases as systemic therapy improves. However, after point A, the role of local therapy decreases as systemic therapy improves, as all cancerous lesions can be cured by systemic therapy at point B.
BRAIN TUMOR

This section and the following four sections focus on organ-specific oligometastases and oligo-recurrence. First, oligometastases and oligo-recurrence of brain metastatic tumors are described.

Classification of metastatic brain tumors such as oligo-recurrence in recursive partitioning analysis (RPA) class I is widely recognized and accepted (6). This class I contains patients with: KPS ≥70; age <65 years; controlled primary; and no extracranial metastases. All RPA class I patients thus show oligo-recurrence. However, RPA class I requires age <65 years, so if age is ≥65 years and even KPS 100, the patient is classified as RPA class II. Rapid progress has recently been made in reducing the invasiveness of surgery and radiotherapy. The age of 65 years is thus no longer the limit of aggressive therapy. The RPA classification was developed in 1997, and more than a decade has passed since the proposal of this classification. Given recent advances in modern medicine, oligo-recurrence is considered to be more appropriate.

Kocher et al. (7) compared 117 patients with one to three previously untreated cerebral metastases who underwent stereotactic radiosurgery (SRS) between 1991 and 1998 with 138 patients with one to three lesions treated using whole-brain radiotherapy (WBRT) between 1978 and 1991. The first modality represents a more powerful treatment of metastatic brain tumors. Of these patients, 32 were classified as RPA class I. Patients thus show oligo-recurrence. However, RPA class I requires age <65 years, so if age is ≥65 years and even KPS 100, the patient is classified as RPA class II. Rapid progress has recently been made in reducing the invasiveness of surgery and radiotherapy. The age of 65 years is thus no longer the limit of aggressive therapy. The RPA classification was developed in 1997, and more than a decade has passed since the proposal of this classification. Given recent advances in modern medicine, oligo-recurrence is considered to be more appropriate.

LIVER TUMOR

SBRT has also been applied to metastatic liver tumors. In 1998, Blomgren et al. reported that a pilot study using 20–40 Gy in one or two fractions to the periphery of the planning target volume (PTV) achieved 95% local control (17). Several prospective studies have recently been reported. Herfarth et al. (18) reported 56 metastatic liver tumors in 33 patients treated with SBRT using 14–26 Gy per fraction (prescribed to 80%), achieving 78% local control. Kavanagh et al. (19) reported 28 metastatic liver tumors in 21 patients treated with SBRT using 12–20 Gy in three fractions to the periphery of the PTV, achieving 93% local control. Mendez Romero et al. (20) reported 34 metastatic liver tumors in 14 patients treated with SBRT using 37.5 Gy in three fractions (prescribed to 65%), achieving 94% local control. In 2009, Rusthoven et al. (21) reported 63 metastatic liver tumors in 57 patients treated with SBRT using 36–60 Gy in three fractions, achieving a 3-year local control rate of 92% and a 2-year overall survival rate of 30%.

BONE

Oligo-recurrence and oligometastases of bone have been reported in breast cancer. The summary is that high-dose radiotherapy relieves pain for a long time and can even improve overall survival.

Niibe et al. (4) reported on solitary bone metastases in seven patients treated with conventional radiotherapy. Six of
seven patients achieved complete remission of pain, which was prolonged at the last follow-up. Only one patient showed relapse of pain. This patient received 30 Gy in 10 fractions (BED₁₀ ≈ 39 Gy), representing the smallest dose in that series (other patients received 40–50 Gy in 20–25 fractions; BED₁₀ ≥ 48 Gy). In 2009, Milano et al. (22) reported 85 metastatic lesions in 40 breast cancer patients treated with SBRT, achieving a 2-year overall survival rate of 76% and a 4-year overall survival of 59%. Among these, the most favorable prognostic factor for breast oligometastatic patients was metastases only involving bone. This indicated high-dose radiotherapy using SBRT for bone metastases could contribute to patient survival.

LYMPH NODES

Oligometastases and oligo-recurrence of distant lymph node metastases have been reported for uterine cervical carcinoma. Uterine cervical carcinoma spreads through the lymphatic route rather than hematogenously (2,23). The first site of distant metastasis of uterine cervical carcinoma is the para-aortic lymph node. This has been confirmed in a large population-based study (2).

Hong et al. (24) reported 35 patients with isolated para-aortic lymph node recurrence treated with concurrent chemoradiotherapy achieving a 5-year overall survival rate of 34%. Kim et al. (25) reported 12 patients treated with hyper-fractionated radiotherapy totaling 60 Gy combined with concurrent chemoradiotherapy, achieving a 3-year overall survival rate of 19%. To date, the largest study has been reported by Niibe et al. (3) in Japan. They reported 84 patients treated with conventional radiotherapy with or without chemotherapy achieved a 5-year overall survival rate of 31.3%, similar to the 38% for 5-year overall survival rate in a previous, small, population-based study in Japan (26). Recently, Choi et al. (27) reported that 30 uterine cervical and corpus cancer patients with isolated para-aortic lymph node recurrence treated by SBRT using a cyberknife achieved a 4-year overall survival of 50.1%.

CONCLUSIONS

Curative local therapy for oligometastases and oligo-recurrence represents a brilliant opening to the era of cancer therapy. Several decades ago, most metastatic and recurrent cancer patients died within a year. However, we cope with metastases or recurrences considering whether the state is oligometastases or oligo-recurrence. In the state of oligo-recurrence, all the gross tumors could be treated with local therapy, meaning curative treatment. However, in the state of oligometastases, clinicians should judge a primary site to be controlled or not before treatment. If the primary site is controlled, meaning oligo-recurrence, they should pursue to cure the patients. However, if the primary site is uncontrolled or extra-target metastases lesions exist, they intend to prolong survival not to pursue cure.

More appropriate target cancers, treatment modalities and schedules should be established for oligometastases and oligo-recurrence. Moreover, adjuvant chemotherapy will improve dramatically because of molecular-targeted drugs. Further clinical studies are required in this field.

Funding

This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Ministry of Health, Labour and Welfare of Japan and Foundation for Promotion of Cancer Research of Japan.

Conflict of interest statement

None declared.

References

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8–10.
2. Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Li N, et al. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol 2006;103:435–8.
3. Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, et al. Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5000. Int J Radiat Oncol Biol Phys 2006;66:1366–9.
4. Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Haru T, et al. Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res 2008;28:3929–31.
5. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399–405.
6. Gaspar L, Scott C, Rotman M, Ashbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.
7. Kocher M, Maarouf M, Bendel M, Voges J, Muller RP, Sturm V. Linac radiosurgery versus whole brain radiotherapy for brain metastases. A survival comparison based on the RTOG recursive partitioning analysis. Strahlenther Onkol 2004;180:263–7.
8. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet 2004;363:1665–72.
9. Niibe Y, Karasawa K, Nankamura O, Shinoura N, Okamoto K, Ymada R, et al. Survival benefit of stereotactic radiosurgery for metastatic brain tumors in patients with controlled primary lesions and no other distant metastases. Anticancer Res 2003;23:4157–60.
10. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37–49.
11. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:94–100.
12. Bloomgren H, Lax I, Naslund I, Vanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator.
Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861–70.

13. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsunatori G, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998;82:1062–70.

14. Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokudo M, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002;51:1041–6.

15. Norishita Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008;72:398–403.

16. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:1579–84.

17. Blomgren H, Lax I, Goranson H, Kraepelien T, Nilsson B, Nåslund I, et al. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg 1998;1:63–74.

18. Herfarthe KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001;19:170. 164.

19. Kavanagh BD, Shetter TE, Cardenes HR, Stieber VW, Ruben D, Timmerman RB, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006;45:848–55.

20. Mendez Romero A, Wuderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol 2006;45:831–7.

21. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572–8.

22. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009;115:601–8.

23. Robert JK, Henry IN, Edward W. Tumors of the cervix. In: Bethesda MD, editor. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology 1992;37–139.

24. Hong HJ, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Recurrent squamous cell carcinoma of the cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249–57.

25. Kim JS, Kim JS, Kim SY, Kim KH, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2003;55:1247–53.

26. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsuji H. Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003;13:849–55.

27. Choi CW, Cho CK, Yoo SY, Kim MS, Yang KM, Yoo HJ, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009;74:147–53.